CSL Ltd (ASX: CSL) — Stock Profile

CSL Limited is a global biopharmaceutical company engaged in the research, development, manufacture, and distribution of biopharmaceutical products and vaccines across Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and a range of other international markets. The company operates through three segments, CSL Behring, CSL Seqirus, and CSL Vifor, each addressing distinct therapeutic needs across a broad patient population.

CSL Behring focuses on plasma products, gene therapies, and recombinants, serving patients with conditions spanning immunology, hematology, cardiovascular and metabolic disease, respiratory conditions, and transplant medicine. CSL Seqirus manufactures and distributes influenza-related products and provides pandemic preparedness services to governments, while CSL Vifor addresses iron deficiency and nephrology through its dedicated product portfolio. The company also licenses its intellectual property as part of its broader commercial operations. Founded in 1916, CSL Limited is headquartered in Melbourne, Australia.